Sp_6B

PreclinicalBiologic

RRadboud University Medical Center

Sp_6B is one of 7 biologic programs targeting Pneumococcal Infection. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Pneumococcal InfectionActive, not recruiting

Pneumococcal InfectionPreclinical

Active, not recruiting

Competition

Competitive Landscape

8 competitors in Pneumococcal Infection

#DrugCompanyPhaseTrials

Prevnar

GSK

Approved

1 2

Fluzone

Sanofi

Phase 3

—3

Pneumovax

NNational Institute of Allergy and Infectious Diseases (NIAID)

Approved

1 4

Rituxan

Synflorix

1 6

Amoxil

GGlobal Antibiotics Research and Development Partnership

Preclinical

1 7

Sp_6B

RRadboud University Medical Center

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Pneumococcal Infection1 trial

A Controlled Human Pneumococcal Infection Model (PIM) Study

Completed·RRadboud University Medical Center·N/A·NCT05361499·20 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Sp_6B. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Sp_6B compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Sp_6B. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Radboud University Medical Center company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[2]
Highest Phase: Preclinical[1]
Company: RRadboud University Medical Center

Sp_6B

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Pneumococcal Infection1 trial

References

Drug Info

Quick Facts

Related News